Inquire Before Buying
Speak to an Analyst 
Request Brochure 
Request CustomizationIMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
Read More
Macular Degeneration Treatment Market Report by Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration), Stage of Disease (Early Stage, Intermediate Stage, Late Stage), Route of Administration (Intravenous Route, Intravitreal Route), End User (Hospitals, Ambulatory Surgical Center, and Others), and Region 2024-2032
Report Format: PDF+Excel | Report ID: SR112024A5118
Buy Now
Market Overview:
The global macular degeneration treatment market size reached US$ 9.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 15.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5.5% during 2024-2032.
|
Report Attribute
|
Key Statistics
|
|---|---|
|
Base Year
|
2023
|
|
Forecast Years
|
2024-2032
|
|
Historical Years
|
2018-2023
|
|
Market Size in 2023
|
US$ 9.4 Billion |
|
Market Forecast in 2032
|
US$ 15.4 Billion |
| Market Growth Rate 2024-2032 | 5.5% |
Macular degeneration is a neurodegenerative ocular disorder that affects the eyes and causes blurred or loss of vision in the center of the visual field. It is characterized by blind spots in the field of vision, visual distortions and inability to see in low light conditions. Some of the commonly used therapeutic techniques for macular degeneration includes anti-angiogenic drugs, photodynamic laser therapies, contact lenses and transitional lenses. Laser therapy involves the insertion of specialized contact lenses into the affected are of the eye, which are sealed by lasers along with the blood vessels. Anti-angiogenic drugs are used for preventing blockages and leakages in the blood vessels. Timely treatment of macular degeneration treatment can aid in enhancing vision and minimizing the risks of developing chronic blindness.
.webp)
Macular Degeneration Treatment Market Trends:
The increasing incidences of age-related macular degeneration and obesity among the masses is one of the key factors driving the market growth. The changing dietary patterns and the rising adoption of sedentary lifestyles is leading to the development of macular degeneration. Additionally, the increasing utilization of smartphones, laptops and television, which is leading to prolonged and excessive screen time is also impacting the occurrence of the disorder. Moreover, the development of retinal gene therapies that involves the injection of adeno-associated virus (AAV) into the body for preventing the development of abnormal blood vessels is providing a thrust to the market growth. In line with this, significant improvements in the healthcare infrastructure is positively impacting the market growth. Other factors, including extensive research and development (R&D) activities for the development of innovative and effective drugs, along with the implementation of various government initiatives for promoting public health, are anticipated to drive the market toward growth.
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
To get more information about this market, Request Sample
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global macular degeneration treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, stage of disease, route of administration and end user.
Breakup by Type:
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
To get more information about this market, Request Sample
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
Breakup by Stage of Disease:
- Early Stage
- Intermediate Stage
- Late Stage
Breakup by Route of Administration:
- Intravenous Route
- Intravitreal Route
Breakup by End User:
- Hospitals
- Ambulatory Surgical Center
- Others
Breakup by Region:
To get more information on the regional analysis of this market, Request Sample
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Iveric Bio Inc., Novartis AG, Panoptica, Pfizer Inc., Phio Pharmaceuticals, Regeneron Pharmaceuticals Inc., Regenxbio Inc. and Santen Pharmaceutical Co. Ltd.
Report Coverage:
| Report Features | Details |
|---|---|
| Base Year of the Analysis | 2023 |
| Historical Period | 2018-2023 |
| Forecast Period | 2024-2032 |
| Units | US$ Billion |
| Segment Coverage | Type, Stage of Disease, Route of Administration, End User, Region |
| Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
| Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
| Companies Covered | Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Iveric Bio Inc., Novartis AG, Panoptica, Pfizer Inc., Phio Pharmaceuticals, Regeneron Pharmaceuticals Inc., Regenxbio Inc. and Santen Pharmaceutical Co. Ltd. |
| Customization Scope | 10% Free Customization |
| Report Price and Purchase Option | Single User License: US$ 3899 Five User License: US$ 4899 Corporate License: US$ 5899 |
| Post-Sale Analyst Support | 10-12 Weeks |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global macular degeneration treatment market was valued at US$ 9.4 Billion in 2023.
We expect the global macular degeneration treatment market to exhibit a CAGR of 5.5% during 2024-2032.
The rising incidences of age-related macular degeneration and obesity, along with the increasing adoption of macular degeneration treatment in enhancing vision and minimizing the risks of developing chronic blindness, are primarily driving the global macular degeneration treatment market.
The sudden outbreak of the COVID-19 pandemic had led to postponement of elective treatment for neurodegenerative ocular disorder to reduce the risk of coronavirus infection upon hospital visits or interaction with healthcare professionals.
Based on the type, the global macular degeneration treatment market has been segmented into dry age-related macular degeneration and wet age-related macular degeneration. Currently, wet age-related macular degeneration holds the majority of the total market share.
Based on the stage of disease, the global macular degeneration treatment market can be divided into early stage, intermediate stage, and late stage. Among these, late stage currently exhibits a clear dominance in the market.
Based on the route of administration, the global macular degeneration treatment market has been categorized into intravenous route and intravitreal route, where intravitreal route accounts for the largest market share.
Based on the end user, the global macular degeneration treatment market can be segregated into hospitals, ambulatory surgical center, and others. Currently, hospitals hold the largest market share.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global macular degeneration treatment market include Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Iveric Bio Inc., Novartis AG, Panoptica, Pfizer Inc., Phio Pharmaceuticals, Regeneron Pharmaceuticals Inc., Regenxbio Inc., and Santen Pharmaceutical Co. Ltd.
Need more help?
- Speak to our experienced analysts for insights on the current market scenarios.
- Include additional segments and countries to customize the report as per your requirement.
- Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
- For further assistance, please connect with our analysts.
Purchase options
Benefits of Customization
Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
UNITED STATES
Phone: +1-631-791-1145
INDIA
Phone: +91-120-433-0800
UNITED KINGDOM
Phone: +44-753-713-2163
Email: sales@imarcgroup.com
Client Testimonials
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
Read More
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
Read More
Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.
Read More.webp)
We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.
Read More
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
Read More
The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.
Read More
My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.
Read More
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
Read More.webp){kind=logo}
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.
Read More
IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.
Read More